On September 10, Insilicon Smart announced that the Rentosertib Phase III clinical trial had completed the enrollment and administration of the first patient at Peking Union Medical College Hospital in China, and that the first patient was enrolled at Shanghai Pulmonary Hospital on the same day. This phase III clinical trial is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel group study to systematically evaluate the efficacy and safety of taking oral Rentosertib once daily for 52 weeks.

On September 10, Insilicon Smart announced that the Rentosertib Phase III clinical trial had completed the enrollment and administration of the first patient at Peking Union Medical College Hospital in China, and that the first patient was enrolled at Shanghai Pulmonary Hospital on the same day. This phase III clinical trial is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel group study to systematically evaluate the efficacy and safety of taking oral Rentosertib once daily for 52 weeks.